Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agkistrodon halys antivenin is a biological product developed for the treatment of snakebites from the Siberian pit viper (*Agkistrodon halys*, also known as *Gloydius halys*). Developed and manufactured by the Jiangxi Biological Products Research Institute, it consists of purified immunoglobulin fragments, typically F(ab')2, obtained from the plasma of healthy horses immunized with the specific venom. The antivenin works by providing passive immunity; the antibodies bind to and neutralize the circulating toxins in the venom, such as proteases and phospholipases, thereby preventing further systemic toxicity, coagulopathy, and local tissue damage. It is a critical therapeutic agent in regions where *Agkistrodon halys* is endemic, particularly in China and Central Asia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on agkistrodon halys antivenin.